TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has made a strategic investment in biotechnology company Junevity and agreed to license applications of Junevity’s RESET Platform for cosmetics. The companies plan to investigate skin-ageing pathways; Amorepacific will lead any cosmetic product development and commercialisation. No product, investment amount or launch timeline was disclosed.
Amorepacific Ventures, the corporate investment arm of the Korean beauty group behind Laneige, has invested in biotechnology company Junevity and signed a separate licensing agreement to explore cosmetic uses of its RESET Platform. The companies say they will study biological pathways involved in skin ageing, with Amorepacific responsible for developing and commercialising any resulting cosmetic products.
Under the collaboration, Junevity will use its RESET Platform to investigate potential skin-ageing pathways relevant to cosmetic applications. The work will combine Junevity’s target-discovery technology with Amorepacific’s expertise in skin biology and product development. The companies describe the intended research as exploring ways to affect skin gene networks toward a healthier state; this is a research objective, not evidence that a product has achieved a rejuvenating effect.
The arrangement has two parts: a strategic investment by Amorepacific Ventures and a separate licensing agreement for cosmetic field applications. Amorepacific is set to lead the development and commercialisation of cosmetics, while Junevity will continue advancing therapeutic applications of its platform. The announcement did not disclose the investment size, licensing terms or ownership details.
Amorepacific R&I Center chief technology officer Brian Byung-Fhy Suh said the collaboration would examine the biology of skin ageing, including gene networks and transcriptional regulation. Junevity co-founder and CEO John Hoekman said the partnership could extend the platform into skin care and other markets. Neither company named a candidate cosmetic, disclosed testing results or gave a target launch date.
A New Research Route for Skin Care
The deal brings a biotechnology target-discovery platform into a consumer beauty company’s cosmetic research and development process. If the research identifies pathways that can be addressed safely and supported by evidence, it could inform future product development. For now, the announcement signals a research partnership, not a confirmed new ingredient, finished product or demonstrated benefit for consumers.
The division of responsibilities also clarifies how the companies expect the work to proceed: Junevity contributes its platform and continues its therapeutic research, while Amorepacific takes the lead on any cosmetics that emerge. That gives the beauty group a route to investigate biological questions about skin ageing while retaining responsibility for cosmetic development and commercialisation. The practical value will depend on results that have not yet been reported.
anti-aging skin care serum with gene targeting
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Therapeutics to Cosmetic Research
Junevity’s platform is described in the announcement as a system for discovering biological targets. The company also has therapeutic research underway: Hoekman referred to a lead siRNA candidate for obesity that he said was headed into human clinical trials. That is separate from the skin-care collaboration, and the supplied report provides no clinical-trial data or evidence that the obesity program will affect cosmetic development.
For Amorepacific, the partnership sits within its research and innovation work. The company owns Laneige and has internal expertise in skin biology, development and commercialisation, according to the source report. The new agreement focuses on exploring Junevity’s technology for cosmetic field applications; it does not establish that therapeutic claims or medical uses will be carried over to consumer products.
““The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.””
— Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center
As an affiliate, we earn on qualifying purchases.
Investment Terms and Product Timing
The announcement does not state how much Amorepacific invested, what licensing fees or other terms apply, or whether the agreement grants exclusivity. It also does not identify specific gene networks or targets that the research will pursue, explain how potential cosmetic applications will be tested, or provide a schedule for reporting results.
There is no named product, formulation, launch date or consumer study in the supplied material. The companies’ language about resetting or rejuvenating skin gene networks describes the intended direction of research; it should not be read as proof that a cosmetic can alter those networks or deliver a particular skin-health outcome. The evidence and regulatory route for any future claims remain unknown.
cosmetic products targeting skin aging pathways
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Research Before Any Product Launch
The companies say they will work together to identify pathways that may be suitable for cosmetic applications. The next meaningful developments would be details on research targets, published or otherwise disclosed findings, and information on how any resulting cosmetic candidate is assessed. No timeline for those milestones was provided.
If the work yields a viable cosmetic concept, Amorepacific is expected to lead its development and commercialisation under the announced division of responsibilities. Junevity, meanwhile, says it will continue advancing therapeutic applications of its platform, including the separate obesity program mentioned by its CEO. The source report does not give a date for an update on either track.
advanced skin longevity moisturizer
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did Amorepacific invest in?
Amorepacific Ventures invested in Junevity, a biotechnology company, and the companies also signed a separate licensing agreement for cosmetic applications of Junevity’s RESET Platform. The investment amount was not disclosed.
What is the RESET Platform intended to do?
Junevity describes it as a platform for discovering biological targets. In this collaboration, the companies plan to use it to investigate skin-ageing pathways that could be relevant to cosmetics. The announcement does not provide findings showing that the platform has produced a cosmetic benefit.
Will a new product be available soon?
No product or launch date was announced. The stated next step is joint research, and Amorepacific will lead development and commercialisation if the work produces a cosmetic candidate.
How is this different from Junevity’s therapeutic research?
The agreement covers cosmetic field applications, while Junevity says it will continue its therapeutic programs separately. Its CEO referred to a lead siRNA candidate for obesity that he said was headed into human clinical trials; the source provided no further trial details.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
